Minimal residual disease (MRD) testing has emerged as a powerful prognostic marker in multiple myeloma, with numerous studies in both newly diagnosed and relapsed/refractory disease (RRMM) demonstrating its strong association with progression-free and overall survival. Increasingly adopted as a surrogate end point in clinical trials, MRD testing is now recognized as an important tool to guide treatment decision-making, yet community uptake remains limited due to logistical barriers, lack of testing resources, and uncertainty around clinical application. In this program, leading hematologist/oncologists share expert guidance on current testing recommendations and the evolving role of MRD in RRMM, discussing how it informs prognosis, treatment planning, and outcomes prediction. Faculty will also address practical strategies to overcome barriers, interpret MRD results, and integrate testing into routine practice ultimately supporting improved patient outcomes in RRMM.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
82% of listed courses are free
78 of 95 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiothoracic Surgery
- Cardiovascular Disease
- Child & Adolescent Psychiatry
- Communication & Shared Decision-Making
- Comprehensive & Board Review
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Otolaryngology
- General Pediatrics
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Medical Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Pain Medicine
- Pediatric Infectious Diseases
- Pediatric Neurology
- Physical Medicine & Rehabilitation
- Practice Management & Ethics
- Preventive Medicine
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Spine Surgery
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Rehabilitation
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1.25 credits
- Commercial Support
-
ReleasedNov 3, 2025
-
Last day to claim creditNov 4, 2026 3 weeks left
-
Kaplan Medical Education Trial Results Suggest a Growing Role for MRD Negativity to Guide Treatment
-
M3 IME B.V +1 Future Directions in Multiple Myeloma. The Impact of CELMoDs, MRD as a Clinical Endpoint, and the Importance of Shared Decision-Making
-
i3 Health Frontline Decisions in NDMM: Case Discussion on Regimen Selection and MRD-Guided Management
-
Haymarket Medical Education The Promise of Emerging CAR Ts in RRMM: Strategies to Improve Adoption in the Community
-
Haymarket Medical Education Next Paradigm Shift in Relapsed/Refractory Multiple Myeloma Is Already Here: New BCMA BsAb/CD38 Antibody Combination Strategies
-
Haymarket Medical Education EXPERT PERSPECTIVE #1 The Evolving Role of CAR-T Therapy in RRMM: Access and Evidence
